Shopping Cart
- Remove All
- Your shopping cart is currently empty
HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC). It promotes acetylation at the TXNIP promoter and increases TXNIP expression, modulating potassium channel activity and inducing TXNIP-dependent potassium deficiency. Additionally, HL23 impedes HCC progression and spread, demonstrating greater potency when combined with Sorafenib than the Sorafenib and Vorinostat duo [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $1,370 | 8-10 weeks | |
50 mg | $2,780 | 8-10 weeks | |
100 mg | $3,700 | 8-10 weeks |
Description | HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC). It promotes acetylation at the TXNIP promoter and increases TXNIP expression, modulating potassium channel activity and inducing TXNIP-dependent potassium deficiency. Additionally, HL23 impedes HCC progression and spread, demonstrating greater potency when combined with Sorafenib than the Sorafenib and Vorinostat duo [1]. |
Molecular Weight | 712.83 |
Formula | C44H44N2O7 |
Cas No. | 1448355-15-4 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.